Helping patients heal faster + live better with medical innovations, new technologies & compassion. Visit https://teapawt.net/t.co/pv7rSELFXT to learn more.
Toronto, Canada
Joined April 2012
- Tweets790
- Following629
- Followers431
- Likes256
Covalon is heading to #AVA2026! Visit Booth 216 to explore VALGuard, CovaClear and IV Clear, and learn how Contamination Protection helps address the “outside-in” contamination pathway across the IV line. Oct. 2-4 | Grapevine, TX #AVASM26
Read More:
bit.ly/4AFyJbC
Covalon announced encouraging real-world evidence findings for its collagen matrix dressing. In diabetic foot ulcers, it showed the highest modeled probability of achieving >50% granulation coverage at 8 and 12 weeks. #WoundCare #Diabetes
Read More: bit.ly/4iNal1j
Covalon will present at the 2026 Smallcap Discoveries Conference on Sept. 28. CEO Brent Ashton will discuss Q3 momentum, profitable growth, and Covalon’s outlook with investors.
#MedTech #Investors #SmallCap
@smallcapdisc
bit.ly/3TFWCPL
Q3 2026: Revenue +20% YoY. EPS of $0.10, greater than past 5 quarters combined. Proud of what we delivered, excited about the even bigger opportunity ahead" -Brent Ashton, CEO
Read More: bit.ly/4ccwnXl
Join us next Thursday, August 27, 2026, at 8:30am ET as we discuss our third quarter financial results and provide updates on our strategic progress.
🔗 bit.ly/4wEIVOm
Read the whole Press Release: bit.ly/4gIsf3K
#InvestorNews #MedTech
We're thrilled to welcome Dr. Murray Miller back to the Covalon Board of Directors as an independent director! A seasoned physician & medtech advisor, Dr. Miller previously served on our Board 2010–2019.
#MedTech #InvestorNews
Read More: bit.ly/4vGzApj
$COV Q2 FY2026 Results (Jan–Mar 2026): 📈 Revenue $8.7M (+15% YoY) | Gross Margin 61.5% (+690bps) | Net Income $1.1M (+155% YoY)
Plus: category creation, product growth, peer-reviewed study, and more !👇 bit.ly/4uowtSB
Read the full press release at ir.covalon.com/news/news-det…
Join us next Thursday, May 21 2026, at 8:30am ET as we discuss our Q2 financial results and provide updates on our strategic progress.
📞 Investors, analysts, and stakeholders all invited
🔗 bit.ly/4wzznWk
#InvestorNews #MedTech
Read the whole Press Release: ir.covalon.com/news/news-det…
Strong momentum for Covalon at INS & SAWC—engaging clinicians, advancing partnerships, and spotlighting the urgent need to address IV contamination. Excited to see this topic featured at APIC & AVA 2026 as awareness and demand for proven solutions grow.
#Nursing #VascularAccess
Read More: ir.covalon.com/news/news-det…
With increasing clinical validation, accelerating sales wins, and expanding business development discussions, Covalon continues to build momentum.
Read More: bit.ly/3MPnfOO
#MedTech #HealthcareInnovation #EarningsUpdate
Join us next Wednesday, February 25, 2026, at 8:30am ET as we discuss our first quarter financial results and provide updates on our strategic progress.
📞 Investors, analysts, and stakeholders welcome
🔗 bit.ly/4c3CXA2
Link in Comments
#InvestorNews #MedTech
Read the full Press Release: ir.covalon.com/news/news-det…
🚀 Covalon Reports Highest Revenue Quarter of FY2025 & 3rd straight year of revenue growth!
💡 Strong commercial execution
💰 First-ever special dividend paid
📈 $32.8M global revenue & $17M cash position
Onward to FY2026! Press Release Link in Comments.
#MedTech #InvestorNews
Join us next Thursday, December 11, at 8:30am ET as we discuss our fourth quarter financial results and provide updates on our strategic progress.
📞 Investors, analysts, and stakeholders are invited to attend.
🔗 bit.ly/4izRHb0
#InvestorNews #MedTech
Read the whole Press Release: ir.covalon.com/news/news-det…